
The Ultimate Visual Guide to Protein: Here's How Much You Should Eat A Day
Your protein needs will vary based on factors like body weight and activity level. A general guideline from the recommended dietary allowance for protein is 0.36 grams per pound of body weight per day. You can use the US Department of Agriculture's calculator for a more tailored estimate.
If you have fitness goals and need help visualizing how much protein you need, this guide is your blueprint for 100 grams of protein across different diets. The protein amounts below are estimates based on specific products and their nutrition labels, so your figures may vary depending on the brand or preparation method. Each picture contains 100 grams of protein combined, not 100 grams per item. If you want to get better at hitting your daily protein goals, this visual guide can help.
What 100 grams of protein looks like for omnivores
Amanda Capritto/CNET
Eating 100 grams of protein per day should be pretty easy if you don't have any dietary restrictions. Here's what that would look like:
Two eggs (12 grams)
Snack cheese (5 grams)
Greek yogurt (15 grams)
Beef sausage (14 grams)
One can of tuna (27 grams)
½ cup of rolled oats (5 grams)
2 ounces of deli ham (10 grams)
1 ounce of mixed nuts (5 grams)
Two slices of rye bread (10 grams)
Everything pictured above comes to 103 grams, which puts you slightly over your daily target.
What 100 grams of animal protein looks like for carnivores
Amanda Capritto/CNET
As you can see, getting 100 grams of protein from animal products doesn't take much:
Four eggs (24 grams)
One can of tuna (27 grams)
Three beef meatballs (15 grams)
2 ounces of turkey bacon (10 grams)
3 ounces of turkey breast (24 grams)
This amounts to a perfect 100 grams of protein. If you ate all of this in a day, plus bread and other nonanimal products, you would surpass 100 grams of protein in a day.
What 100 grams of protein looks like for vegetarians
Amanda Capritto/CNET
For vegetarians, 100 grams of protein might look like this:
Four eggs (24 grams)
½ cup of rolled oats (5 grams)
Two snack cheeses (10 grams)
¼ cup of protein granola (10 grams)
A single-serve Greek yogurt (15 grams)
One tablespoon of hemp seeds (4 grams)
Two tablespoons of peanut butter (7 grams)
One scoop of plant-based protein powder (20 grams)
This comes out to 99 grams of protein, which is pretty close.
What 100 grams of protein looks like for vegans
Amanda Capritto/CNET
What you see isn't totally what you get with the amount of protein here:
1 ounce of nuts (5 grams)
½ cup of rolled oats (5 grams)
A protein granola bar (8 grams)
Two slices of rye bread (10 grams)
¼ cup of protein granola (10 grams)
One tablespoon of hemp seeds (4 grams)
Two tablespoons of chia seeds (10 grams)
Two tablespoons of peanut butter (7 grams)
One scoop of plant-based protein powder (20 grams)
This amounts to 79 grams of protein. If we double up on the mixed nuts, chia seeds and hemp seeds, this brings us to 93 grams of protein. You could add an extra tablespoon of peanut butter or eat a full cup of oats, instead of half a cup, to come closer to 100 grams.
This plate also excludes high-protein vegan meat substitutes, such as tofu, tempeh or plant-based meats like the Impossible Burger. Those food sources can make it easier to get 100 grams of protein for someone who eats a vegan diet.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
5 minutes ago
- Medscape
Self-Management Asthma App Boosts Symptom Control in Adults
TOPLINE: In adults with asthma, a digital asthma self-management (DASM) program improved symptom control compared with usual care, although its effectiveness varied by race, with weaker results observed among African American participants. METHODOLOGY: Researchers conducted a randomized trial to evaluate the impact of a DASM program on symptom control among adults with asthma. A total of 899 participants (mean age, 36.6 years; 71.1% women; approximately 61.3% with uncontrolled asthma) were recruited via email between October 2020 and November 2021 to receive either the DASM program (n = 450) or usual care (n = 449). All the enrolled participants installed a custom smartphone app and utilized wearable devices during the trial. The DASM group received a full-featured self-management version with symptom tracking and alerts, whereas the usual care group received a limited version with only the asthma control test and collection of patient-reported outcomes. The primary outcomes included the 12-month change from baseline in asthma control test scores (scores ≤ 19 indicated uncontrolled asthma), and secondary outcomes included participants' counts of symptom logs and patient-reported outcomes. TAKEAWAY: Among participants with uncontrolled asthma, the DASM intervention improved mean asthma control test scores by 4.6 points at 12 months compared with a 1.8-point improvement with usual care (adjusted difference, 2.8 points; P < .001). The treatment effect varied by race, with between-group differences in asthma control test scores showing improvements of 1.0 point (P = .26) in African American participants and 3.3 points (P < .001) in non-African American participants. Symptom logging rates were comparable across insurance and ethnicity subgroups, with no significant differences observed. However, African American participants logged symptoms less frequently than non-African American participants. Patient-reported outcomes — self-reported medication adherence, readiness to change self-management behaviors, confidence in the ability to manage one's health, and asthma-related work productivity impairment — also favored the DASM intervention over usual care (P ≤ .001 for all). IN PRACTICE: 'Findings reveal an opportunity to adapt the DASM program for more consistent effects throughout diverse populations. Future research is needed — quantitative and qualitative — to elucidate causes of differences in outcomes,' the authors wrote. SOURCE: The study was led by Jordan Silberman, MD, PhD, Office of Medical Policy and Technology Assessment, Elevance Health, Palo Alto, California. It was published online on July 17, 2025, in JAMA Network Open. LIMITATIONS: The study was limited by the requirement for iPhone ownership, exclusion of uninsured participants, lack of blinding, and potential for biased missingness despite robust sensitivity analyses. DISCLOSURES: This study was funded by Elevance Health, Inc. (formerly Anthem Inc.), with support from Apple Inc. Three authors declared receiving financial support from Apple or grants from Elevance Health. One author reported receiving stock from Elevance Health. Few other authors reported receiving financial aid from the University of California and pharmaceutical companies, including Pfizer, AstraZeneca, and Eli Lilly and Company. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Associated Press
6 minutes ago
- Associated Press
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ('Lucid' or the 'Company') a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 financial results. The webcast will be available at the investor relations section of the Company's website at Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name 'Lucid Diagnostics Business Update' to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at About Lucid Diagnostics Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit and for more information about its parent company PAVmed, please visit View original content to download multimedia: SOURCE Lucid Diagnostics


Associated Press
6 minutes ago
- Associated Press
NeuralBase to Acquire HeartEase, Set to Revolutionize Enterprise Wellness and Preventive Health Diagnostics
LAS VEGAS, NV - July 30, 2025 ( NEWMEDIAWIRE ) - NeuralBase AI Ltd. (OTC: NBBI), operating under its enterprise brand BMP AI and a growing innovator in enterprise artificial intelligence, is pleased to announce that it has executed an agreement to acquire HeartEase, a cutting-edge AI-powered diagnostic platform that uses smartphone microphones to detect early signs of heart abnormalities. This strategic acquisition marks a bold step in NeuralBase's mission to integrate wellness-focused, preventive healthcare solutions into its enterprise AI chatbot ecosystem. With rising demand from corporations and institutions for integrated employee wellness solutions, NeuralBase recognized a growing gap in tools that go beyond mental health chatbots and provide actionable health diagnostics. HeartEase fills this need by enabling non-invasive, accessible, and real-time heart health screening through mobile devices - a perfect complement to BMP AI's enterprise-focused chatbot technology. 'We believe that HeartEase will become a revolutionary platform as it harnesses the power of artificial intelligence and mobile technology to provide early detection of heart abnormalities. Unlike traditional diagnostics, it requires no external hardware - only a smartphone,' stated Vighnesh Dobale, CEO of NeuralBase. Key Features of HeartEase are expected to include: This targeted acquisition represents a transformational shift in how enterprises can care for their workforce. BMP AI's chatbot platform already supports companies with intelligent task automation, HR interactions, and employee engagement tools. The addition of HeartEase allows enterprises to take employee care to a whole new level by integrating preventive health screening into the daily digital experience - right on employees' smartphones. 'With HeartEase, we're not just improving enterprise chatbot functionality - we're redefining how technology can protect and empower people in their everyday lives,' added Dobale. 'We see this as the foundation for a broader wellness initiative that supports both mental and physical health across global workplaces.' The backend AI engine of HeartEase is already fully trained using validated clinical datasets, and mobile integration is underway. A Minimum Viable Product (MVP) is slated for rapid field testing in Q4 2025, with pilots targeting enterprise clients, wellness programs, and rural health campaigns. As businesses increasingly recognize the ROI of employee wellness, from lower healthcare costs to higher productivity and retention, NeuralBase's acquisition of HeartEase is set to deliver a unique competitive edge. It places the company at the forefront of AI-driven preventive healthcare, bridging the gap between enterprise tech and real-world impact. With this move, NeuralBase continues its commitment to building technologies that scale ethically, inclusively, and intelligently, transforming how companies operate. The closing of the transaction is subject to the completion of customary due diligence and the satisfaction of other closing conditions. NeuralBase will provide further updates if and when available. Additional information about the Company is available at or by visiting About NEURALBASE AI LTD. NeuralBase AI Ltd. (OTC: NBBI) is an AI company developing secure, scalable, and context-aware conversational agents and workflow automation systems. Through its BMP AI platform - now in beta testing - the company enables organizations to streamline internal operations, enhance team collaboration, and increase productivity while maintaining strict compliance and data integrity. Legal Disclaimer and Forward-Looking Statements This press release contains forward-looking statements as defined under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, estimates, projections, and assumptions made by NeuralBase AI Ltd. (the 'Company' or 'NBBI') in light of experience, current conditions, anticipated future developments, and other factors. Forward-looking statements may include words such as 'aims,' 'anticipates,' 'believes,' 'plans,' 'expects,' 'intends,' 'will,' 'may,' 'could,' 'should,' and similar expressions. These statements relate to, among other things, the expected performance and capabilities of the BMP AI platform; the Company's ability to successfully complete product development, enter commercial deployment, or scale its technology; future revenues and market expansion; and general strategic direction. All such statements are inherently uncertain and involve a number of risks that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. NeuralBase AI Ltd. is a fully reporting company with the U.S. Securities and Exchange Commission (SEC) and files annual and quarterly reports, current reports, and other required disclosures. All public filings and disclosures may be reviewed at the SEC's EDGAR database at The Company trades on the OTC Markets under the ticker symbol NBBI. This press release is not, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of NeuralBase AI Ltd. in the United States or in any other jurisdiction. Offers and sales of securities, if any, will be made only pursuant to an effective registration statement or valid exemption under the U.S. Securities Act of 1933, as amended. Investing in securities traded on the OTC Markets involves significant risk, including potential loss of principal, low liquidity, high volatility, and limited publicly available information. Shares traded on the OTC Markets may be more susceptible to market manipulation or price swings. Investors are strongly advised to conduct their own due diligence, consult a qualified investment advisor, and carefully review all SEC filings prior to making any investment decision. Media Contact: Vighnesh Dobale Chief Executive Officer [email protected] (727) 314-3717 View the original release on